As the panelists suggest methods to help control the costs of agents for the treatment of multiple sclerosis (MS) and improve patient care, Gary M. Owens, MD, explains that the US needs to aggressively review a drug’s cost versus its value and make products that do not provide outcomes sufficient to their costs more difficult for clinicians to access and treat patients with.
Dr Owens explains that because clinicians treat their MS patients at a population level, clinical guidelines are a necessity.
Leslie Fish, PharmD, agrees and believes that it is important that healthcare professionals receive clinical data about treatment effectiveness for certain patient populations.
Patricia K. Coyle, MD, suggests that improvements in MS disease activity biomarkers can also help clinicians make more educated decisions about treatment.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Moving Evidence From Research to Practice: Q&A With Ken Cohen, MD
June 23rd 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.
Read More
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Read More